Soligenix Inc. (NASDAQ:SNGX – Get Free Report) was the recipient of a large drop in short interest during the month of October. As of October 30th, there was short interest totaling 66,373 shares, a drop of 59.3% from the October 15th total of 162,935 shares. Approximately 0.5% of the company’s shares are sold short. Based on an average trading volume of 90,729 shares, the days-to-cover ratio is currently 0.7 days.
Soligenix Stock Down 8.7%
SNGX stock traded down $0.03 during trading on Monday, hitting $0.29. The company had a trading volume of 223,761 shares, compared to its average volume of 2,289,809. Soligenix has a 52-week low of $0.28 and a 52-week high of $1.70. The company has a 50 day simple moving average of $0.36 and a 200-day simple moving average of $0.64. The firm has a market capitalization of $6.85 million, a P/E ratio of -0.65 and a beta of 2.04.
Soligenix (NASDAQ:SNGX – Get Free Report) last released its quarterly earnings data on Friday, November 6th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.05. Sell-side analysts forecast that Soligenix will post -0.55 earnings per share for the current year.
Analysts Set New Price Targets
Get Our Latest Stock Report on Soligenix
About Soligenix
Soligenix, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare diseases and other serious medical conditions. Its work spans therapeutic programs for inflammatory and immunological disorders, as well as vaccine and medical countermeasure development. The company’s BioTherapeutics programs include HyBryte (SGX301), a topical treatment based on synthetic hypericin being developed for cutaneous T-cell lymphoma, and dusquetide (SGX942), which has been studied for oral mucositis associated with cancer treatment.
See Also
- Five stocks we like better than Soligenix
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.
